RecruitingNot ApplicableNCT07086118

Dexamethasone Versus Metoclopramide for Prophylaxis of Nausea and Vomiting After Cataract Surgery

Efficacy of Dexamethasone Versus Metoclopramide for Prophylaxis of Nausea and Vomiting After Cataract Surgery: A Double-blind Randomized Controlled Study


Sponsor

Alexandria University

Enrollment

210 participants

Start Date

May 1, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Postoperative nausea and vomiting (PONV) is a common consequence of ambulatory surgery, affecting up to 80% of high-risk patients and 20-30% overall. Despite being widespread, a prior survey found that patients are more averse to PONV than pain and other significant postoperative problems. Furthermore, even mild cases of PONV can have serious repercussions, such as postanesthesia care unit (PACU) workflow disruption, delayed discharges, higher medical costs, and lower patient satisfaction.PONV following intraocular surgery can be unpleasant and may lead to serious complications including suprachoroidal hemorrhage (SCH). SCH is a potentially serious condition that occurs when the posterior ciliary arteries or vortex veins burst, resulting in blood in the suprachoroidal region. The hypothesis is that dexamethasone will lower the incidence of PONV after cataract surgery when compared with metoclopramide.


Eligibility

Min Age: 40 YearsMax Age: 80 Years

Inclusion Criteria2

  • Age: 40-80 years, both sexes.
  • ASA physical status class I to III.

Exclusion Criteria6

  • history of motion sickness
  • patients with gastrointestinal disorders or gastro-oesophageal reflux
  • patients taking medications with known antiemetic activity
  • previous postoperative vomiting
  • allergy to bupivacaine
  • allergy to metoclopramide or dexamethasone

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHER0.9% normal saline

patients in group P will receive 0.9% normal saline

DRUGMetoclopramide 10mg

patients in group M will receive 10 mg metoclopramide

DRUGDexamethasone

patients in group D will receive 8 mg dexamethasone


Locations(1)

Alexandria University

Alexandria, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07086118


Related Trials